Low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis jirovecii pneumonia in HIV-uninfected patients: a systematic review and meta-analysis
BackgroundTrimethoprim-sulfamethoxazole (TMP-SMX) is the recommended first-line prophylactic agent against Pneumocystis jirovecii pneumonia (PJP). However, the standard regimen is often discontinued due to its drug-associated adverse events (AEs), especially in immunocompromised patients without HIV...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2025-07-01
|
| Serier: | Frontiers in Pharmacology |
| Fag: | |
| Online adgang: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1545436/full |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
